UGGC Avocats is noted for its broad practice which spans the full spectrum of contentious and regulatory healthcare issues. The group regularly advises on the commercialisation of medical devices and medicines, including labelling issues and product composition. Practice head Sylvie Welsch primarily focuses on disputes involving medical liability, and non-contentious matters concerning health product advertising and distribution. Malka Marcinkowski is particularly adept at advising on pharma laboratories and medical device manufacturers on antitrust investigations and the regulations governing health products.
Legal 500 Editorial commentary
Key clients
- AdBio partners
- Tridek-One
- Therinvest
- ANS
- Centre Hospitalier Universitaire de Guadeloupe
- Advent France biotechnology
- Innothera Group
- Olmix Group
- GIM
- DocCity
- Bpifrance
Work highlights
- Acted for AdBio Partners in their acquisition of French biotech company SynHelix, specialised in DNA synthesis technology,by Belgian group Univercells, specialised in the manufacture and marketing of equipment forthe production of drugs, vaccines and biotreatments.
- Assisted Tridek-One, a biotech start-up specialising in the research and development of CD31 agonists to restore immune balance, in raising €16 million from new investors Pureos BioVentures, Bpifrance through its InnoBio2 fund, Bioqube Ventures and existing investors AdBio Partners, Advent Life Sciences.
- Advised ANS (Agence du Numérique en Santé -Digital Health Agency) on the tendering of the new public contract for the connection and management of emergency medical services: advice on the tender, management of the risk of litigation, and legal advice on securing the tender (IT reversibility).
Practice head
The lawyer(s) leading their teams.
Sylvie Welsch